CHIMERIC THERAPEUTICS

CHIMERIC

PIONEERS IN CELL THERAPY

Clinical Trial Update 2025

ASX:
CHM

2025

DISCLAIMER

Certain statements contained in this presentation, including, without limitation, statements containing the words **"believes,"** "**plans**," "**expects**," "**anticipates**," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, "Chimeric" or the "Company") to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products.

Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.

INVESTMENT HIGHLIGHTS

- **4 Phase 1 clinical trials**
  under 3 FDA INDs at 4 leading US centres
- **Multiple clinical updates**
  in the next 12mths
- **Experienced leadership team**
  in cell therapy clinical development
- CHM-CDH17
  the FIRST CDH17 CAR-T in clinical trials
- **First in class**
  CLTX-CAR for brain cancer
- **Robust and long life**
  patent portfolio

CORPORATE PROFILE

Exchange	ASX: CHM
Share Price	$0.003
52 Week Range	$0.002 - 0.017
Market Cap	~ 10m
Shares on issue	~3.2B
IPO 2021	

CHM LEADERSHIP TEAM

EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALISATION

Dr Rebecca McQUALTER
Chief Executive Officer

Dr Jason LITTEN
Chief Medical Officer



Dr Stephanie ASTROW
Chief Scientific Officer

EXPERIENCE	50+	Years of Cell Therapy Experience
EXPERTISE	50+	Development Programs
RESULTS	5/7	FDA-Approved CAR T Cell Therapies

AMGEN · JUNO THERAPEUTICS · Celgene · Kite · YESCARTA · TECARTUS · NOVARTIS · Fate THERAPEUTICS · artiva · KYMRIAH (tisagenlecleucel) Suspension for IV infusion · Abecma · Breyanzi

CHIMERIC THERAPEUTICS

2025

CHM: BROAD PORTFOLIO

3 Novel cell therapies; 4 Clinical Trials

CHM CDH17

CAR-T

Technology from:

Penn
University of Pennsylvania

PHASE 1/2 TRIAL OPEN

4 sites active

CHM CORE-NK

'OFF THE SHELF' NK

Technology from:

CASE WESTERN RESERVE UNIVERSITY

PHASE 1B TRIAL OPEN	PHASE 1B TRIAL OPEN
MD Anderson	Case Western

CHM CLTX

Technology from:

City of Hope

Phase 1A completed: COH

PHASE 1B TRIAL

1 site active

CHIMERIC THERAPEUTICS

CHM CDH17

Clinical Trial Update

October 2025

2025

CDH17 OVERVIEW

- Over a decade of development at the world-renowned cell therapy centre, The University of Pennsylvania
- Compelling pre-clinical efficacy in gastric, pancreatic and neuroendocrine Cancers
- Pre-clinical models indicate no toxicity in healthy cells
- This is the first CDH17 CAR-T Cell Therapy in clinical trials in the world
- CDH17 is protein on the surface of Gastrointestinal cancers (green on purple cell in picture)


Dr. Xianxin Hua, M.D., Ph.D.


Dr. Carl June M.D.



ENCOURAGING PRE-CLINICAL RESULTS

CDH17 CAR T induced complete eradication of tumours with no relapse in seven mouse models



NEUROENDOCRINE TUMOURS



GASTRIC CANCER



PANCREATIC CANCER



CHM CDH17

CAR-T

Penn
University of Pennsylvania

Source: Feng et al., Nature Cancer, 2022

CHM CDH17 CAR-T PHASE 1 RECRUITING

The first CDH17 CAR T cell therapy in clinical trials globally

CHIMERIC THERAPEUTICS

2025

CHM CDH17
CAR-T

Technology from:

Penn
University of Pennsylvania

PHASE 1/2 TRIAL OPEN

4 sites actively recruiting

PERSONALISED CAR-T: AUTOLOGOUS

4 prestigious sites recruiting: Sarah Cannon, UPenn, Uchiacgo, Emory

FDA IND clearance: Nov 23

FDA FASTRACK GRANTED

Manufacturing: 10/10 successful runs; GMP Compliant

Phase 1/2 Trial Open in Colorectal, Gastric and Neuroendocrine Cancers

10 Patients enrolled:

8 Patients treated, 2 awaiting dosing assignment

N= up to 15 patients

Phase 1/2 Clinical Trial of CHM CDH17 Design



NCT06501183

CHM CDH17 PROGRESS AS AT OCT 8TH, 2025

Dose Level	Status	Notes
1 50m	Completed	4 patients treated 1 patient remains on study
2 150m	Recruitment Ongoing	4 patients treated
3 450m	Recruitment underway	2 patients awaiting dosing assignment
Manufacturing	GMP compliant	10 out of 10 successful runs

CLINICAL PRELIMINARY RESULTS

DOSE LEVEL 1 COMPLETED

50m Cells	Tumour Type	Status
Patient 1	CRC	No follow up
Patient 2	NET	Stable Disease until day 150 progression Grade 1 CRS
Patient 3	**CRC**	**Stable Disease at day 300.**
Patient 4	CRC	Progressive Disease at day 28

CRC= Colorectal Cancer (Bowel Cancer)
NET= NeuroEndocrine Tumor (Intestinal NET)

CLINICAL PRELIMINARY RESULTS

CHIMERIC THERAPEUTICS

DOSE LEVEL 2 Ongoing

150m Cells	Tumour Type	Status
Patient 5	**CRC**	**Stable Disease 90days** **Tumour Shrinkage 12%**
Patient 6	**NET**	**Stable Disease** **Tumour Shrinkage 6%-37%**
Patient 7	CRC	Treated.
Patient 8	CRC	Treated.

CRC= Colorectal Cancer (Bowel Cancer)
NET= NeuroEndocrine Tumor (Intestinal NET)

CHM CDH17 PROGRESS

RECRUITMENT UNDERWAY

TBD Dose of Cells	Tumour Type	Status
Patient 9	NET	Manufactured. Dose yet to be assigned
Patient 10	NET	Manufactured. Dose yet to be assigned
TBD		
TBD		

CRC= Colorectal Cancer (Bowel Cancer)
NET= NeuroEndocrine Tumor (Intestinal NET)

CHM CDH17 CAR-T cells expand and persist



TOTAL GLOBAL MARKET SIZE



https://www.grandviewresearch.com/industry-analysis/pancreatic-cancer-treatment-market
https://www.grandviewresearch.com/industry-analysis/stomach-cancer-gastric-cancer-market
https://www.grandviewresearch.com/industry-analysis/colorectal-cancer-crc-drugs-therapeutic-market

SUMMARY + FY26 CATALYSTS

CHM CDH17
CHM 2101

- 8 patients treated
- 10/10 manufacturing runs
- Anti-tumour activity observed
- No safety issues to date
- No off-target effects

FY26 Deliverables

- Complete Dose level 2
- Commence Dose level 3 (if appropriate)
- Conclude Phase 1
- Phase 2 readiness

CHIMERIC THERAPEUTICS

CHM CORE NK

Clinical Trial Update

October 2025

2025

CHM CORE-NK 2 PHASE 1B TRIALS OPEN

Phase 1b clinical trials OPEN

CHM CORE-NK
'OFF THE SHELF' NK

Technology from:

CASE WESTERN RESERVE UNIVERSITY

PHASE 1B TRIAL OPEN	PHASE 1B TRIAL OPEN
MD Anderson	Case Western

OFF THE SHELF: ALLOGENEIC

NK cell expansion platform: Universal Donor

Positive Phase 1A Clinical Trial in AML

Two ongoing Phase 1B Clinical Trials in AML + CRC

MDACC AML: Cohort 1 cleared, moved to dose expansion for Cohort 2 FRONTLINE - A FIRST IN CELL THERAPY
1 Patient dosed; rapidly recruiting

Case Western AML + CRC: 4 patients dosed

Foundation for asset development

AML PHASE 1B CLINICAL TRIAL OPEN

CHM CORE-NK + AZA + VEN in FRONTLINE AML

Clinical Trials.gov Identifier: NCT05834244

THE UNIVERSITY OF TEXAS MD Anderson Cancer Center



CORE NK CELLS

FDA REGISTERED CHEMOTHERAPY

FDA REGISTERED BLOOD CANCER DRUG

CHM CORE NK

'OFF THE SHELF' NK

CHIMERIC THERAPEUTICS

2025

CHM CORE-NK FRONTLINE PHASE 1 STUDY RESULTS

Four Completes Responses, 1 Partial Response

Dose escalation completed



Relapse Refractory Patients
1 Complete Response

First line Dosing Underway



FrontLine Patients with no prior treatment
3 Complete Responses
1 Partial Response

Complete Response means that all visible or measurable signs of cancer have disappeared after treatment
Partial Response means the cancer has reduced by at least 50% but not entirely disappeared in response to treatment

SUMMARY CHM CORE-NK

CHM CORE-NK

'OFF THE SHELF' NK

Investigator Sponsored Trial – MD ANDERSON

Dose Escalation competed

First Line Dosing Underway – up to 20 patients

No safety issues to date

FY26 Deliverables

Complete dosing of 20 patients; subject to MD Anderson

SUMMARY

CHM CDH17

CHM 2101

- 8 patients treated
- 10/10 manufacturing runs
- Tumour shrinkage observed
- No safety issues to date
- No off-target effects

CHM CORE-NK

'OFF THE SHELF' NK

- Investigator Sponsored Trial – MD ANDERSON
- Dose Escalation completed
- First Line Dosing Underway – 7 dosed up to 20 patients
- No safety issues to date

CHIMERIC THERAPEUTICS

CHIMERIC

PIONEERS IN CELL THERAPY

investors@chimerictherapeutics.Com

2025